Treatment
Figure 1. Management of Metastatic HR-Positive Breast Cancer
Patients with metastatic hormone
receptor positive breast cancer with
disease progression on a prior endocrine
agent with or without targeted therapy
Oral PARP
inhibitor in the
first through
third line
setting
Single agent chemotherapy is the
preferred option, but combination
regimens may be offered for symptomatic
or immediately life-threatening disease
Endocrine therapy with or without
targeted therapy or single agent
chemotherapy
Receiving benefit
from endocrine
therapy?
Germline BRCA1 or
2 mutations?
NO
NO
YES
YES
